Abstract:Background Muscle-invasive bladder cancer continues to lack reliable diagnostic and prognostic biomarkers. Recently, tumor vaccines targeting specific molecules have emerged as a promising treatment in inhibiting tumor progression, which was rekindled under the background of coronavirus disease-2019 pandemic. However, the application of mRNA vaccine targeting muscle-invasive bladder cancer–specific antigens remains limited, and there has been a lack of comprehensive studies or validations to identify suitable patient subgroups for vaccination. This study aims to explore novel muscle-invasive bladder cancer antigen signatures to identify patients most likely to benefit from vaccination. Methods Gene expression profiles of muscle-invasive bladder cancer samples, along with corresponding clinical data, were retrieved from the Cancer Genome Atlas Program. The least absolute shrinkage and selection operator model was applied to develop signatures for stratifying muscle-invasive bladder cancer patients. Prognostic accuracy of each factor was assessed using receiver operating characteristic analysis. Tumor Immune Estimation Resource was employed to visualize the relationship between the proportion of antigen-presenting cells and the expression of selected genes. The CIBERSORT and WGCNA R packages were used to identify differences in immune infiltration levels across muscle-invasive bladder cancer subgroups. Additionally, the STRING database and Cytoscape were used to construct the protein-protein interaction network. CCK-8 and colony formation assays were employed in invitro experiments. Results A total of 49 potential tumor antigens were identified. Using least absolute shrinkage and selection operator Cox regression, 14 tumor antigens were selected to develop a risk evaluation signature. The risk score signature can serve as a valuable tool for predicting the outcomes of muscle-invasive bladder cancer patients. Based on differential clinical, molecular, and immune-related gene profiles, muscle-invasive bladder cancer patients were classified into 2 subtypes: the immune “cold” subtype (immune score 1) and the immune “hot” subtype (immune score 2). The immune score signature, developed using a logistic score model, effectively distinguishes between patients more likely to belong to immune score 1 or 2. Notably, patients with a high risk score exhibited a higher proportion of immune score 2 compared to those with a low risk score. Additionally, the prognostic accuracy was significantly enhanced when the risk score and immune score were combined. Different tumor subtypes displayed distinct immune landscapes and signaling pathways. Moreover, novel tumor antigens associated with oxidative stress were identified. Conclusion The risk score and immune score signatures based on tumor antigens have identified potential effective neo-antigens for the development of mRNA vaccines targeting muscle-invasive bladder cancer. Patients with low risk score and immune score 1 subtype are more likely to benefit from mRNA vaccination. Additionally, this study highlights the critical role of oxidative stress in modulating the efficacy of the mRNA vaccine.

The Epitope Basis of Embryonic Stem Cell‐induced Antitumor Immunity against Bladder Cancer

Identification of Tumor-Antigen Signatures and Immune Subtypes for Mrna Vaccine Selection in Muscle-Invasive Bladder Cancer

Immunization with Embryonic Stem Cells/Induced Pluripotent Stem Cells Induces Effective Immunity Against Ovarian Tumor-Initiating Cells in Mice

Vaccination with human pluripotent stem cells generates a broad spectrum of immunological and clinical responses against colon cancer.

Enhancing immune responses of ESC-based TAA cancer vaccines with a novel OMV delivery system

Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development

Expression Levels of a Gene Signature in Hipsc Associated with Lung Adenocarcinoma Stem Cells and Its Capability in Eliciting Specific Antitumor Immune‐response in a Humanized Mice Model

Whole-exome Sequencing Predicted Cancer Epitope Trees of 23 Early Cervical Cancers in Chinese Women

Exosome-based cancer vaccine for prevention of lung cancer

Vaccination With Embryonic Stem Cells Generates Effective Antitumor Immunity Against Ovarian Cancer

Identification of tumor antigens and immune landscapes for bladder urothelial carcinoma mRNA vaccine

Administration of embryonic stem cells generates effective antitumor immunity in mice with minor and heavy tumor load

Synthesis of the mutant sequences for HER2 and survivin mimetic peptides of bladder cancer

Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer

Bladder cancer stem cells: clonal origin and therapeutic perspectives.

Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells

Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.

Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma

Human embryonic stem cells--a potential vaccine for ovarian cancer.

An Effective Approach to Prevent Immune Rejection of Human ESC-derived Allografts.

Induced Pluripotent Stem Cells as a Novel Cancer Vaccine.